MANNKIND CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $MNKD in the last 7 days.
MannKind (MNKD) partnered with Rose Pharma to develop ROSE-010, an inhaled weight-loss drug. The deal gives MannKind equity, royalties, and a board seat. ROSE-010 has completed Phase 2a trials showing weight loss and pain relief. MannKind reported Q2 revenue of $109.4M, up 43% YoY, with recent FDA approvals and positive trial data.
MannKind (MNKD) and Rose Pharma agreed to develop ROSE-010, an inhaled GLP-1 receptor agonist for weight management. MannKind licenses its Technosphere tech, gets equity and royalties. ROSE-010 showed promise in weight loss and IBS pain relief trials. MNKD stock closed at $4.16, up 2.46%.
MannKind (MNKD) announced a global licensing deal with Rose Pharma for an inhaled GLP-1 therapy. The company's P/S ratio is 3.29, below historical and industry medians. GF Value™ suggests a 44.2% undervaluation, but financial risks remain high. Insiders and gurus show cautious activity.
Recent MNKD coverage spans financial news, technology and regulation.
In the last 30 days, MNKD insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($256K). The most active reporter was Binder Steven B. with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The deal gives MannKind exposure to a large weight‑loss market with limited downside, potentially supporting the stock.
The deal gives MannKind equity and royalty upside while expanding Rose Pharma's pipeline.
The deal provides MannKind with equity, board seats and potential royalties, potentially boosting future revenue streams.
The deal expands MannKind's pipeline into the fast‑growing GLP‑1 market and could boost future revenue.
Regulatory approval unlocks new pediatric market, boosting revenue potential.
AlphAI scores every news story that mentions MNKD with an AI model for sentiment and relevance, and aggregates insider trades from MANNKIND CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
MannKind (MNKD) partnered with Rose Pharma to develop ROSE-010, an inhaled weight-loss drug. The deal gives MannKind equity, royalties, and a board seat. ROSE-010 has completed Phase 2a trials showing weight loss and pain relief. MannKind reported Q2 revenue of $109.4M, up 43% YoY, with recent FDA approvals and positive trial data.
2 min readMannKind (MNKD) and Rose Pharma agreed to develop ROSE-010, an inhaled GLP-1 receptor agonist for weight management. MannKind licenses its Technosphere tech, gets equity and royalties. ROSE-010 showed promise in weight loss and IBS pain relief trials. MNKD stock closed at $4.16, up 2.46%.
1 min readMannKind (MNKD) announced a global licensing deal with Rose Pharma for an inhaled GLP-1 therapy. The company's P/S ratio is 3.29, below historical and industry medians. GF Value™ suggests a 44.2% undervaluation, but financial risks remain high. Insiders and gurus show cautious activity.
3 min readMannKind (MNKD) partners with Rose Pharma to develop ROSE-010, an inhaled weight-loss drug using Technosphere technology. MannKind will receive an equity stake and potential royalties. ROSE-010 showed weight loss and reduced calorie intake in prior studies. MNKD shares rose 1.7% in pre-market trading.
2 min readMannKind (MNKD) shares rose 5% after FDA approved Afrezza for diabetes treatment in children aged 6+. The approval follows Phase 3 trial data showing Afrezza's noninferiority to injections in HbA1c changes, with higher patient satisfaction and less weight gain. Afrezza uses Technosphere tech for rapid insulin delivery via inhalation.
2 min readThe FDA accepted United Therapeutics' NDA for ralinepag, a PAH treatment, with a PDUFA target date of June 24, 2027. The application is based on Phase III trial results showing a 55% reduction in clinical worsening events. If approved, ralinepag would be the first once-daily oral prostacyclin IP receptor agonist for PAH. The company also plans to develop a dry powder inhalation formulation with MannKind.
2 min readMannKind (MNKD) filed a prospectus supplement for the resale of up to 12.85 million shares of common stock by existing selling stockholders, including 2.41 million shares issuable upon exercise of pre-funded warrants. The company will not receive proceeds from the resale but will cover registration expenses. The shares were last traded at $4.26 on August 20, 2026.
2 min readMannKind Corp. (MNKD) filed a prospectus supplement and a legal opinion from Cooley LLP for a common stock offering under its shelf registration on Form S-3. The Form 8-K filing includes the opinion, supporting the planned sale of common stock. The SEC filing was made on August 21, 2026.
1 min readThree Connecticut firms outlined different financing paths. New Silver said it acquired Mayflower Venture Partners to expand lending in New England, with deal terms undisclosed. American Battery Materials filed to raise about $16.3M for Utah lithium and magnesium exploration, targeting production in 2029. MannKind raised $50M after FDA approval of Furoscix ReadyFlow, funding a $45M milestone payment and aiming for U.S. sales by end-August.
6 min readMannKind (MNKD) shares rose 5.1% after the company reported Q2 2026 revenue of $109.37 million, up from $76.53 million a year earlier, but a net loss of $19.03 million versus a small net profit. MannKind also released positive Phase 1b inhaled nintedanib DPI safety data for idiopathic pulmonary fibrosis.
6 min read
